Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. News
  7. Press Releases
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société OTSUKA HOLDINGS CO., LTD.
01/27OTSUKA : Notice Regarding Revisions of Consolidated Results Forecast for FY2021
PU
2021Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December..
PU
2021OTSUKA : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the T..
BU
2021OTSUKA : Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and Licen..
PU
2021Dry Eye Syndrome Market 2026|Industry Analysis with Top Manufacturers- Allergan, Alcon,..
AQ
2021OTSUKA : Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities..
AQ
2021OTSUKA : Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities..
PU
2021OTSUKA : and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Va..
PU
2021OTSUKA : Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restri..
PU
2021OTSUKA : Decision to continue phase III clinical trial evaluating brexpiprazole for treatm..
PU
2021H LUNDBECK A/S : Lundbeck and Otsuka announce decision to continue phase III clinical tria..
AQ
2021OTSUKA : and Akebia Announce Submission of New Drug Application to the FDA for Approval of..
PU
2021OTSUKA : appoints Board Members and Audit & Supervisory Board Members (147KB)
PU
2021OTSUKA : Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation
PU
2021OTSUKA : Notice of Change of Certified Public Accountant (161KB)
PU
2021OTSUKA : announces FY2020 financial results
PU
2021OTSUKA : Office Divisions of Five Otsuka Group Companies to Switch to Green Power
AQ
2021OTSUKA : Office Divisions of Five Otsuka Group Companies to Switch to Green Power (102KB)
PU
2021OTSUKA : Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Devel..
AQ
2020OTSUKA : Health Comic Library Celebrates 30 Years
AQ
2020OTSUKA : Health Comic Library Celebrates 30 Years Revamped website aims to further contrib..
PU
2020OTSUKA : Announces Results of Two International Clinical Studies in Patients with Treatmen..
PU
2020OTSUKA : announces 3Q FY2020 financial results
PU
2020OTSUKA : ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in ..
PU
2020OTSUKA : announces 2Q FY2020 financial results
PU
2020OTSUKA : Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and..
AQ
2020OTSUKA : announces 1Q FY2020 financial results
PU
2020OTSUKA : Notice regarding Postponement of the Announcement of Consolidated Financial Resul..
AQ
2020OTSUKA : Notice regarding Postponement of the Announcement of Consolidated Financial Resul..
PU
2020OTSUKA : appoints Board Members and Audit & Supervisory Board Members (192KB)
PU
2020OTSUKA : Chemical Announces Personnel Changes
AQ
2020OTSUKA : Chemical Announces Personnel Changes (187KB)
PU
2020OTSUKA : Announces Personnel Changes
AQ
2020OTSUKA : Announces Personnel Changes (193KB)
PU
2020OTSUKA : announces FY2019 financial results
PU
2019OTSUKA : Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd.
AQ
2019OTSUKA : Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd. (1..
PU
2019OTSUKA : Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial..
PU
2019OTSUKA : Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MA..
PU
2019OTSUKA : Adopts CO2-free Electricity Annual CO2 Emissions to Decline by Approximately 9% (..
PU
2019OTSUKA : announces 2Q FY2019 financial results
PU
2019OTSUKA : Notice concerning amendments to the forecasts for the first half of FY2019 (88KB)
PU
2019OTSUKA : Electronics Announces Personnel Changes (96KB)
PU
2019OTSUKA : announces the Third Medium-Term Management Plan (65KB)
PU
2019OTSUKA : Notice Regarding Company Split (Simplified Absorption–type Company Split) (..
PU
2019OTSUKA : Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation (8..
PU
2019OTSUKA : appoints Board Members and Audit & Supervisory Board Members (194KB)
PU
2019OTSUKA : Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational..
PU
2019OTSUKA : and Lundbeck report phase III data evaluating brexpiprazole for the treatment of ..
PU
2018OTSUKA : Notice Regarding Company Split (Simplified Absorption–type Company Split) (..
PU
2018OTSUKA : Pharmaceutical Completes Acquisition of Visterra (84KB)
PU
2018OTSUKA : announces 2Q FY2018 financial results
PU
2018OTSUKA : Notice concerning amendments to the forecasts (IFRS) for the first half of FY2018..
PU
2018OTSUKA : and Lundbeck's Rxulti® (brexpiprazole) approved by the European Commission (82KB)
PU
2018OTSUKA : Pharmaceutical to Acquire Visterra (127KB)
PU
2018OTSUKA : and Lundbeck's Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP ..
PU
2018OTSUKA : and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in th..
PU
2018OTSUKA : and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in th..
BU
2018OTSUKA : announces 1Q FY2018 financial results
PU
2018OTSUKA : JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow K..
PU
2018OTSUKA : REXULTI® Tablets, a New Antipsychotic Drug, Launched in Japan (81KB)
PU
2018OTSUKA : Announces Personnel Changes (162KB)
PU
2018OTSUKA : announces FY2017 financial results.
PU
2018OTSUKA : Notice concerning amendments to financial forecasts for FY 2017 (87KB)
PU
2018OTSUKA : Signs Statement of Support for Women's Empowerment Principles (218KB)
PU
2018OTSUKA : Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug..
PU
2017OTSUKA : Notice Regarding Company Split (Simplified Absorption–type Company Split) (..
PU
2017OTSUKA : announces 3Q FY2017 financial results
PU
2017OTSUKA : FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in ..
BU
2017OTSUKA : U.S. FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvapta..
PU
2017OTSUKA : Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polyc..
PU
2017OTSUKA : Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polyc..
BU
2017OTSUKA : Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polyc..
BU
2017OTSUKA : Health Canada Approves Otsuka and Lundbeck's Abilify Maintena® (Aripiprazole Once..
BU
2017OTSUKA : and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in the..
PU
1  2  3Next
Upcoming event on OTSUKA HOLDINGS CO., LTD.